New
Vitiligo Study For Children Ages 6-11, International
International clinical trial · Children ages 6–11 · Phase 3
This international study is evaluating ruxolitinib cream in children ages 6–11 with nonsegmental vitiligo. Its use in children this age is investigational — researchers are still finding out how well it works and how safe it is.
The same active ingredient is being studied in TRuE-ViP. Both are Phase III trials, but the age ranges and participating countries are different. Here is what a parent needs to know before adding a clinical trial to the family calendar.
Two studies, same active ingredient: what is the difference?
This international study · NCT06804811
For children ages 6–11, with sites across Argentina and 13 European countries. About 250 children are expected to participate.
TRuE-ViP study · NCT06548360
For children ages 2–11, at selected sites in the United States and Canada. About 180 children are expected to participate.
Is there a study site near you?
Trial sites are located at 79 sites across 14 countries:
Argentina, Austria, Belgium, Bulgaria, Denmark, France, Germany, Hungary, Italy, the Netherlands, Poland, Portugal, Spain and the United Kingdom.
Explore the World Vitiligo Map locations, then contact the research team to ask whether screening may be appropriate.
Check out locations on the map→Why study the cream in children?
Ruxolitinib cream — marketed as Opzelura for approved uses in older patients in several countries — has not been established for this younger age group. This study is designed to evaluate its efficacy and safety in children ages 6–11.
And a younger child is not a pocket-sized teenager. Researchers need real evidence from this age group. The answer is not known yet — that is why the trial exists.
Who may qualify?
- Children ages 6 to 11 at the study start
- A clinical diagnosis of nonsegmental vitiligo, the most common form
- Vitiligo sized from a few small spots up to 10% of the body
Detailed criteria may include other health and treatment requirements. Contact the study team for details.
Quick answers for parents
The questions mothers ask first
You do not need to decode a research protocol over breakfast. Start with the question sitting at the top of your list, and look for more inside.
FAQ 1 · The basics
Why does age matter — and which study may apply?
Learn why children are studied in separate age groups, how a trial differs from regular treatment and why an 8-year-old may fit both studies by age but only one by location.
Read the basics →FAQ 2 · Taking part
What does joining actually look like?
Cream in the morning. Cream at night. Scheduled visits, photographs and blood tests. For the first 24 weeks, your child may receive ruxolitinib cream or a look-alike cream without the active medicine.
See what joining involves →FAQ 3 · Safety and choice
Who watches my child—and can we leave?
See who monitors safety, why other vitiligo treatments may need to pause and what happens if the trial no longer feels right for your child or your family.
Read about safety and leaving →Interested in this international vitiligo study?
Review the countries and current locations, then contact research team to discuss eligibility by email or phone.
View details and contacts of this international trial →Recruitment status, participating countries and site availability can change. The study team will explain eligibility, procedures, possible benefits, risks and alternatives before enrollment.
Suggested Reading
A few short guides for families comparing the two studies, understanding clinical trials and planning the wider vitiligo journey.
Parallel study
Vitiligo Study For Children Ages 2–11 in USA and Canada
The companion guide to TRuE-ViP, the parallel ruxolitinib cream study at selected sites in the United States and Canada.
Clinical trials
Clinical Trials: An Important Step in Drug Development
How treatments move from the laboratory into human studies — and what each phase is meant to learn.
Patient journey
Vitiligo Patient Journey Map
Diagnosis, treatment, setbacks and daily life, mapped like a subway system.
🎙 Listen to Deep Dive in Vitiligo
Start with the two-study explainer in English or Spanish. For the bigger picture, Episode 25 explains how clinical trials work.
Podcast · Ep. 75 · English
Two Pediatric Vitiligo Trials: Same Cream, Different Continents (Ep. 75)
Why two Phase 3 trials are testing the same ruxolitinib cream in different age groups and regions — and how families can tell which study applies to them.
Podcast · Ep. 75 · Español
Dos ensayos de ruxolitinib en niños con vitiligo: misma crema, distinto mapa (Ep. 75)
Una guía clara sobre los dos ensayos pediátricos de ruxolitinib: qué comparten, en qué se diferencian y cuál corresponde según la edad y el país.
Podcast · Ep. 25
Inside Vitiligo Clinical Trials: Why, What and How? (Ep. 25)
A practical conversation about how trials work and what participation can mean.
FAQOther Questions
- Is it possible to stop the progression of vitiligo?
While it's not always possible to quickly stop vitiligo progression, there are some treatments that can help slow or halt the spread of the condition in many cases: Corticostero...
- Awareness Days Similar to World Vitiligo Day
World Vitiligo Day, celebrated annually on June 25 since 2012, is a significant event dedicated to raising awareness about vitiligo and supporting those affected by the conditio...
- What is vitiligo?
Vitiligo (pronounced vit-ill-EYE-go) is a generally unpredictable skin disease that causes a gradual loss of skin color and overlying hair on different parts of the body. Contr...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.